Skip to content
  • Sunday, 26 July 2026
  • 1:47 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Evogene and ELEO Forge Strategic Alliance to Pioneer Next-Generation Oral PCSK9 Inhibitors for Cardiovascular Disease
Pharmaceutical R&D

Evogene and ELEO Forge Strategic Alliance to Pioneer Next-Generation Oral PCSK9 Inhibitors for Cardiovascular Disease

Teuku Ryan Jul 24, 2026 0

Evogene and ELEO have officially announced a significant scientific collaboration poised to accelerate the discovery and development of novel oral…

Read More
Pharmaceutical R&D

Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases

Teuku Ryan Apr 16, 2026 0

Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…

Read More
Yale Researchers Uncover Molecular Mechanism of Sperm-Egg Blocking Antibody Opening New Paths for Fertility and ContraceptionUnlocking Evolutionary Speed: Flipped DNA Segments Drive Rapid Species DiversificationScience News: Empowering Public Understanding of Science, Medicine, and Technology Since 1921Breakthrough in Solid-State Battery Research Reveals How Lithium Dendrites Fracture Ceramic Electrolytes
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ